Related Experiment Video

Updated: Jun 6, 2026

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
07:14

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

Artemisinins in malaria treatment in the UK

    Drug and Therapeutics Bulletin
    |November 9, 2010
    PubMed

    More Related Videos

    Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors05:28

    Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors

    Published on: May 12, 2022

    Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine08:31

    Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine

    Published on: October 11, 2019

    Related Concept Videos

    Anthelminthic Agents01:15

    Anthelminthic Agents

    Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
    Malaria01:29

    Malaria

    Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
    Antiprotozoal Agents01:21

    Antiprotozoal Agents

    Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
    Venous Thrombosis III: Interprofessional Care01:29

    Venous Thrombosis III: Interprofessional Care

    Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

    Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
    ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
    Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

    Antiasthma Drugs: Muscarinic Receptor Antagonists

    Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
    Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...